Alentis Therapeutics Secures $181M to Advance Targeted Therapies for Solid Tumors Alentis Therapeutics, a leading biopharmaceutical company developing targeted treatments for cancer and fibrotic diseases, has secured $181.4 million in Series D funding round to develop targeted therapies for solid tumors. The financing round was spearheaded by OrbiMed, Novo Holdings, and JEITO, with significant contributions from new investors Longitude Capital, Frazier Life Sciences, Catalio Capital Management, Avego, and Piper Heartland Healthcare Capital. Existing investors RA Capital Management, MORNINGSIDE VENTURES LIMITED, Bpifrance, and BB Pureos, along with key institutional investors, participated in the round. Read more: https://nextdigitalhealth.com/funding-news/alentis-therapeutics-secures-181m-to-advance-targeted-therapies-for-solid-tumors/ #HealthcareNews #HealthcareInnovation #HealthcareTechnology #DrugDiscovery #FundingNews